BIO-TECHNE CORP overview

Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results PR Newswire MINNEAPOLIS, July 17, 2025 MINNEAPOLIS , July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025 , at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date:...

Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access to Spear Bio’s groundbreaking SPEAR UltraDetect™ immunoassays, focusing initially on the neurology research...

Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection PR Newswire MINNEAPOLIS, July 15, 2025 MINNEAPOLIS , July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's...

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy PR Newswire MINNEAPOLIS, July 14, 2025 MINNEAPOLIS , July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB),...

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development PR Newswire MINNEAPOLIS, June 24, 2025 MINNEAPOLIS , June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to...

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics PR Newswire ST. PAUL, Minn., June 10, 2025 ST. PAUL, Minn. , June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India . "The blood cancer...

Bio-Techne to Present at Investor Conferences PR Newswire MINNEAPOLIS, May 29, 2025 MINNEAPOLIS , May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: William Blair 45 th Annual Growth Stock Conference June 3, 2025 2:40 PM CDT Jefferies Global Healthcare Conference June 4, 2025 3:45 PM EDT Goldman Sachs 46 th Annual Global Healthcare Conference June 10, 2025 10:40 AM EDT A live webcast of the presentations...

ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) PR Newswire ST. PAUL, Minn., May 14, 2025 ST. PAUL, Minn. , May 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California ( USC ) and the...